- Thinly traded Accelerate Diagnostics (AXDX -0.3%) slips in early trade, albeit on turnover of only 80K shares, on the heels of a bearish report from SA Contributor White Diamond Research (WDR).
- WDR believes the company's flagship Pheno system is only a niche product since design limitations prevent it from replacing tissue culture.
- H1 sales were a modest $3.6M, up 43% from a year ago, but well below sales that would justify its $1B market cap.
- WDR sees almost 70% downside risk in the stock with its $6 price target.
Accelerate Diagnostics slips on bearish WDR report
Recommended For You
About AXDX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AXDX | - | - |
Accelerate Diagnostics, Inc. |